rAAV2tYF-PR1.7-hCNGB3

Drug Profile

rAAV2tYF-PR1.7-hCNGB3

Alternative Names: AAV-PR1.7-hCNGBco vector; AAV2tYF-PR1.7-hCNGB3co; AAV5-PR2.1-hCNGB3; AAV5-PR2.1-hCNGB3co; AAV9-PR1.7-hCNGB3co; ACHM B3; ACHM CNGB3

Latest Information Update: 07 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Applied Genetic Technologies Corporation
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action CNBG3 gene expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colour vision defects
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Colour vision defects

Most Recent Events

  • 01 Feb 2016 Phase-I/II clinical trials in Colour vision defects in USA (Subconjunctival) (NCT02599922)
  • 07 Jan 2016 Pharmacodynamics data from a preclinical trial in Achromatopsia released by AGTC
  • 06 Jan 2016 Applied Genetic Technologies Corporation enter into collaboration with BCM Families Foundation to develop Adeno-associated virus-based gene therapies for the treatment of X-linked achromatopsia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top